BROMFENAC solution/ drops

BROMFENAC by

Drug Labeling and Warnings

BROMFENAC by is a Prescription medication manufactured, distributed, or labeled by Gland Pharma Limited, GLAND PHARMA LIMITED. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    Bromfenac ophthalmic solution 0.09% is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

  • 2 DOSAGE AND ADMINISTRATION

    2.1 Recommended Dosing

    For the treatment of postoperative inflammation in patients who have undergone cataract extraction, one drop of Bromfenac ophthalmic solution should be applied to the affected eye(s) once daily beginning 1 day prior to cataract surgery, continued on the day of surgery, and through the first 14 days of the postoperative period.

    2.2 Use with Other Topical Ophthalmic Medications

    Bromfenac Ophthalmic Solution ophthalmic solution may be administered in conjunction with other topical ophthalmic medications such as alpha-agonists, beta-blockers, carbonic anhydrase inhibitors, cycloplegics, and  mydriatics. Drops should be administered at least 5 minutes apart.

  • 3 DOSAGE FORMS AND STRENGTHS

    Topical ophthalmic solution: bromfenac 0.09%.

  • 4 CONTRAINDICATIONS

    None.

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Sulfite Allergic Reactions

    Contains sodium sulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people.

    5.2 Slow or Delayed Healing


    All topical nonsteroidal anti-inflammatory drugs (NSAIDs) may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.

    5.3 Potential for Cross-Sensitivity

    There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.

    5.4 Increased Bleeding Time


    With some NSAIDs, there exists the potential for increased bleeding time due to interference with platelet aggregation. There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery.


    It is recommended that Bromfenac ophthalmic solution be used with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time.

    5.5 Keratitis and Corneal Reactions


    Use of topical NSAIDs may result in keratitis. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration or corneal perforation. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs and should be closely monitored for corneal health.


    Post-marketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients.


    Post-marketing experience with topical NSAIDs also suggests that use more than 24 hours prior to surgery or use beyond 14 days post surgery may increase patient risk for the occurrence and severity of corneal adverse events.

    5.6 Contact Lens Wear

    Bromfenac Ophthalmic Solution should not be administered while wearing contact lenses.

  • 6 ADVERSE REACTIONS

    6.1 Clinical Trial Experience

    The most commonly reported adverse experiences reported following use of bromfenac after cataract surgery include: abnormal sensation in eye, conjunctival hyperemia, eye irritation (including burning/stinging), eye pain, eye pruritus, eye redness, headache, and iritis. These events were reported in 2 to 7% of patients.

    6.2 Post-Marketing Experience

    The following events have been identified during post-marketing use of bromfenac ophthalmic solution 0.09% in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The events, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to topical bromfenac ophthalmic solution 0.09% or a combination of these factors, include corneal erosion, corneal perforation, corneal thinning, and epithelial breakdown. [see Warnings and Precautions (5)]

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy


    Teratogenic Effects : Pregnancy Category C. Reproduction studies performed in rats at oral doses up to 0.9 mg/kg/day (1300 times the recommended human ophthalmic dose [RHOD]) and in rabbits at oral doses up to 7.5 mg/kg/day (11,000 times RHOD) revealed no evidence of teratogenicity due to bromfenac. However, 0.9 mg/kg/day in rats caused embryo-fetal lethality, increased neonatal mortality, and reduced postnatal growth. Pregnant rabbits treated with 7.5 mg/kg/day caused increased post-implantation loss. 


    There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.


    Nonteratogenic Effects:


    Because of the known effects of prostaglandin biosynthesis-inhibiting drugs on the fetal cardiovascular system (closure of ductus arteriosus), the use of Bromfenac ophthalmic solution during late pregnancy should be avoided.

    8.3 Nursing Mothers

    Caution should be exercised when Bromfenac ophthalmic solution is administered to a nursing woman.

    8.4 Pediatric Use

    Safety and efficacy in pediatric patients below the age of 18 have not been established.

    8.5 Geriatric Use

    There is no evidence that the efficacy or safety profiles for Bromfenac ophthalmic solution differ in patients 65 years of age and older compared to younger adult patients.

  • 11 DESCRIPTION

    Bromfenac ophthalmic solution 0.09% is a sterile, topical, nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Each mL of Bromfenac ophthalmic solution contains 1.035 mg bromfenac sodium (equivalent to 0.9 mg bromfenac free acid). Bromfenac sodium is designated chemically as sodium 2-amino-3-(4-bromobenzoyl) phenylacetate sesquihydrate, with an empirical formula of C15 H11 BrNNaO3 1½H O. The structural formula for bromfenac sodium is:



    Bromfenac-spl-structure

    Bromfenac sodium is a yellow to orange crystalline powder. The molecular weight of bromfenac sodium is 383.17. Bromfenac ophthalmic solution is supplied as a sterile aqueous 0.09% solution, with a pH of 8.3. The osmolality of Bromfenac ophthalmic solution is approximately 300 mOsmol/kg.


    Each mL of Bromfenac ophthalmic solution contains:
    Active: bromfenac sodium hydrate 0.1035%
    Preservative: benzalkonium chloride (0.05 mg/mL)
    Inactives: boric acid, disodium edetate (0.2 mg/mL), polysorbate 80 (1.5 mg/mL), povidone (20 mg/mL),sodium borate, sodium sulfite anhydrous (2 mg/mL), sodium hydroxide to adjust pH and water for injection, USP.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action


    Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that has anti-inflammatory activity. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2.


    Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure.

    12.3 Pharmacokinetics

    The plasma concentration of bromfenac following ocular administration of 0.09% Bromfenac ophthalmic solution in humans is unknown. Based on the maximum proposed dose of one drop to the eye (0.045 mg) and PK information from other routes of administration, the systemic concentration of bromfenac is estimated to be below the limit of quantification (50 ng/mL) at steady-state in humans.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility


    Long-term carcinogenicity studies in rats and mice given oral doses of bromfenac up to 0.6 mg/kg/day (900 times the recommended human ophthalmic dose [RHOD] of 1.67 mcg/kg in 60 kg person on a mg/kg/basis, assuming 100% absorbed) and 5 mg/kg/day (7500 times RHOD), respectively revealed no significant increases in tumor incidence.


    Bromfenac did not show mutagenic potential in various mutagenicity studies, including the reverse mutation, chromosomal aberration, and micronucleus tests.


    Bromfenac did not impair fertility when administered orally to male and female rats at doses up to 0.9mg/kg/day and 0.3 mg/kg/day, respectively (1300 and 450 times RHOD, respectively).

  • 14 CLINICAL STUDIES

    14.1 Ocular inflammation and pain following cataract surgery


    Clinical efficacy was evaluated in three randomized, double-masked, placebo-controlled trials in which subjects requiring cataract surgery were assigned to Bromfenac ophthalmic solution or placebo. Patients were dosed with one drop per eye starting the day before surgery and continuing for 14 days. The primary endpoint was clearing of ocular inflammation by day 15. An additional efficacy endpoint was the number of patients who were pain free on day 1 after cataract surgery.


    In 2 of the 3 studies, Bromfenac ophthalmic solution had statistically significant higher incidence of completely clearing inflammation (46% to 47% vs. 25% to 29%) and also had a statistically significant higher incidence of subjects that were pain free at day 1 post cataract surgery (83% to 89% vs. 51% to 71%).

  • 16 HOW SUPPLIED/STORAGE AND HANDLING


    Bromfenac ophthalmic solution 0.09% is supplied in a 5 ml Screw neck bottle (White LDPE) with a Nozzle (White LDPE) Screw cap (Grey color- HDPE) as follows:


    1.7 mL in 5 mL container (NDC: 68083-313-01)


    STORAGE


    Store at 15º to 25ºC (59º to 77ºF).

  • 17 PATIENT COUNSELING INFORMATION

    17.1 Slowed or Delayed Healing

    Patients should be advised of the possibility that slow or delayed healing may occur while using NSAIDs.

    17.2 Sterility of Dropper Tip

    Patients should be advised to not touch dropper tip to any surface, as this may contaminate the contents.

    17.3 Concomitant Use of Contact Lenses

    Contact lenses should not be worn during the use of this product.

    17.4 Concomitant Topical Ocular Therapy

    If more than one topical ophthalmic medication is being used, the medicines should be administered at least 5 minutes apart.


    Manufactured by:
    Gland Pharma Limited
    Hyderabad, India.
    January 2018

  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    Bromfenac Ophthalmic Solution-0.09%
    NDC: 68083-313-01
    Carton Label
    Bromfenac-SPL-Carton.jpg


    Container Label
    Bromfenac-SPL-Container.jpg
     

  • INGREDIENTS AND APPEARANCE
    BROMFENAC 
    bromfenac solution/ drops
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 68083-313
    Route of AdministrationOPHTHALMIC
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    BROMFENAC SODIUM (UNII: 8ECV571Y37) (BROMFENAC - UNII:864P0921DW) BROMFENAC0.9 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    BENZALKONIUM CHLORIDE (UNII: F5UM2KM3W7) 0.05 mg  in 1 mL
    BORIC ACID (UNII: R57ZHV85D4)  
    EDETATE DISODIUM (UNII: 7FLD91C86K)  
    POLYSORBATE 80 (UNII: 6OZP39ZG8H)  
    POVIDONE K30 (UNII: U725QWY32X)  
    SODIUM BORATE (UNII: 91MBZ8H3QO)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    SODIUM SULFITE (UNII: VTK01UQK3G)  
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 68083-313-011 in 1 CARTON03/17/2020
    11.7 mL in 1 BOTTLE, DROPPER; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21102903/17/2020
    Labeler - Gland Pharma Limited (918601238)
    Establishment
    NameAddressID/FEIBusiness Operations
    GLAND PHARMA LIMITED918601238ANALYSIS(68083-313) , MANUFACTURE(68083-313) , PACK(68083-313)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.